Leerink Partners Maintains Outperform on Veradermics, Raises Price Target to $150

Benzinga · 1d ago
Leerink Partners analyst Marc Goodman maintains Veradermics (NYSE:MANE) with a Outperform and raises the price target from $135 to $150.